Study of ZG005 in Patients With Advanced Solid Tumors
Interventional
Phase 2
Sun Yat-sen University Cancer Center
Sponsor: Zelgen Biopharmaceuticals
Last Updated: January 5, 2026 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
* Life expectancy ≥ 12 weeks;
* Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Exclusion Criteria
* Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
* Any other malignancy within 5 years.
Do you think this trial is incorrectly appearing?
Design Details
AllocationN/A
Intervention ModelSingle Group Assignment
MaskingNone (Open Label)
Number to Enroll100
Arms & Interventions
Arms
Interventions
Type: Experimental
Description: ZG005 dose expansion was performed in different tumors, such as: nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and other carcinoma